TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s approval, offering a promising treatment for HER2 IHC 3+ advanced colorectal cancer, a condition with limited effective treatment options. The drug has shown a 34.8% objective response rate in clinical trials, indicating significant potential to improve patient outcomes in a field where current therapies have limited efficacy.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development and commercialization of pharmaceutical products. The company is involved in creating innovative drugs, particularly in the oncology sector, and operates with a market focus on China.
YTD Price Performance: 147.15%
Average Trading Volume: 160,441,487
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.5B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.